12:00 AM
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Serevent salmeterol: Phase III started

Brigham and Women's Hospital began the open-label, U.S. Phase III BELT trial to compare twice-daily 50 µg Serevent salmeterol or twice-daily 12 µg Foradil formoterol plus inhaled corticosteroid controller medication (ICS) vs. 18 µg once-daily

Read the full 183 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >